# Nuclide record pb-212-psv359 (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/pb-212-psv359/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "pb-212-psv359" ;
  schema:name "Lead-212 PSV359"@en ;
  schema:alternateName "[212Pb]PSV359"@en, "PSV359"@en, "PSV377 (imaging analogue)"@en ;
  schema:description "A drug that homes to the scaffolding cells tumours build around themselves, carrying a radioactive metal that fires alpha particles over a very short range. A matching scan version shows first whether a patient's tumour has the target."@en ;
  schema:url <https://nuclide.cc/drugs/pb-212-psv359/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://www.perspectivetherapeutics.com/pr/perspective-therapeutics-announces-clinical-collaboration-and-supply-agreement-with-merck-to-evaluate-212pbpsv359-in-combination-with-keytruda-pembrolizumab-in-fap-a-positive-solid-tumors>, <https://clinicaltrials.gov/study/NCT06710756>, <https://www.perspectivetherapeutics.com/pipeline/> ;
  nuclide:status "phase-1" ;
  nuclide:tag "FAP", "lead-212", "alpha", "NSCLC" ;
  nuclide:modality "Alpha-emitting radioligand (FAP-alpha targeted)" ;
  nuclide:related <https://nuclide.cc/companies/perspective-therapeutics/>, <https://nuclide.cc/targets/fap/>, <https://nuclide.cc/technologies/fapi-pet/>, <https://nuclide.cc/isotopes/pb-212/>, <https://nuclide.cc/drugs/pb-212-vmt-alpha-net/>, <https://nuclide.cc/technologies/targeted-alpha-therapy/>, <https://nuclide.cc/indications/nsclc/>, <https://nuclide.cc/companies/merck/>, <https://nuclide.cc/drugs/pembrolizumab/> ;
  nuclide:indications <https://nuclide.cc/indications/nsclc/> ;
  nuclide:targets <https://nuclide.cc/targets/fap/> ;
  nuclide:trials <https://nuclide.cc/trials/nct06710756/> .